Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] EXXELERATE: a negative trial with importance for clinical practice

Drug management of rheumatoid arthritis has undergone a large improvement during the past 10–15 years. The current treatment strategy focuses on early initiation of treatment with disease-modifying antirheumatic drugs (DMARDs), in particular with methotrexate as the anchor drug.1 A treatment target (remission) should be established, patients should be monitored closely, and treatment should be changed if the target is not reached within a prespecified time period.